Pharmaceuticals

Fighting Diseases

We Care

01:30

00:00

September 18, 2023

Not intended for UK Media

Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator

August 29, 2023

Gene Editing: Pairwise and Bayer start new five-year multi-million Dollar collaboration to further advance short-stature corn

August 28, 2023

Not intended for UK Media

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

August 21, 2023

Heike Prinz appointed to Board of Management of Bayer AG

August 10, 2023

Not intended for U.S. and UK Media – Two-year topline results from the pivotal study PULSAR:

Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years

August 08, 2023

Bayer Group:

Second quarter impacted by declines in glyphosate business

July 24, 2023

Bayer lowers full-year outlook

June 29, 2023

Not intended for U.S. and UK Media

Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

June 22, 2023

Not intended for U.S. and UK Media

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

June 20, 2023

Crop Science Innovation Summit 2023:

Bayer sees more than doubling of accessible markets and potential to shape regenerative agriculture on more than 400 million acres

May 23, 2023

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

Bayer issues new senior bonds with a volume of 3 billion euros

May 16, 2023

Not intended for UK Media

Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program

May 11, 2023

Bayer Group business performance in the first quarter of 2023:

Slow start to the year as expected

May 10, 2023

Not intended for U.S. and UK Media

Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion

April 28, 2023

CEO Werner Baumann at the Annual Stockholders’ Meeting:

“Bayer has excellent prospects for the future”

April 05, 2023

Bayer to invest a total of 60 million euros in its Ukrainian seed production site

April 03, 2023

Internationally renowned experts form independent Bayer Bioethics Council

Bayer establishes Bioethics Council

March 21, 2023

UN 2023 Water Conference:

Bayer pledges to help tackle global water crisis with new water strategy

March 20, 2023

Not intended for U.S. and UK Media

Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China

March 01, 2023

Not intended for U.S. and UK Media

Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer

March 01, 2023

Not intended for U.S. and UK Media

Bayer submits aflibercept 8 mg for marketing authorization in Japan

February 28, 2023

Fiscal 2022

Bayer: Significant growth in sales and earnings

February 27, 2023

Not intended for U.S. and UK Media

Nubeqa™ approved for additional indication in Japan

February 10, 2023

Not intended for U.S. and UK Media

Kerendia™ (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

February 06, 2023

Not intended for U.S. and UK Media

Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU

January 31, 2023

Bayer to distribute pheromone-based biological crop protection solutions from M2i Group

January 27, 2023

Not intended for U.S. and UK Media

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

January 10, 2023

Not intended for U.S. and U.K. Media

Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros

December 16, 2022

Not intended for U.S. and UK Media

Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

December 14, 2022

Bayer recognized as leader on climate change for fifth consecutive year

November 29, 2022

Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros

November 11, 2022

Not intended for U.S. and UK Media

Bayer receives positive CHMP opinion for Eylea™ in the EU for treatment of preterm infants with retinopathy of prematurity

November 08, 2022

Third quarter of 2022

Bayer with continued strong performance

October 17, 2022

Not intended for U.S. and UK Media

Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy

October 05, 2022

Bayer completes sale of its Environmental Science Professional business to Cinven

September 08, 2022

Not intended for U.S. and UK Media

Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients

September 01, 2022

Kimberly Mathisen appointed to the Supervisory Board of Bayer AG

August 28, 2022

Not intended for U.S. and UK Media

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

August 18, 2022

Bayer supports demining in Ukraine with donation to non-profit “Fondation suisse de déminage”

August 11, 2022

Bayer Showcases Leadership in Breakthrough Innovations and Sustainable, Tailored Solutions to Meet Global Challenges in Agriculture

August 08, 2022

Not intended for U.S. and UK Media

U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

August 04, 2022

Second quarter of 2022

Bayer: Strong growth, outlook raised

July 14, 2022

Bayer to sell men’s health product Nebido™ to Grünenthal

June 29, 2022

Not intended for U.S. and UK Media

Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology